Search

Author/Creator Dylla, Douglas E.

1. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. (11th September 2021)

Authors:
Zamor, Philippe J.; Brown, Ashley; Dylla, Douglas E.; Dillon, John F.; Luetkemeyer, Anne F.; Feld, Jordan J.; Mutimer, David; Ghalib, Reem; Crown, Eric; Lovell, Sandra S.; Hu, Yiran; Moreno, Christophe; Nelson, David R.; Colombo, Massimo; Papatheodoridis, Georgios; Rockstroh, Juergen K.; Skoien, ...
Journal:
American journal of gastroenterology
Issue:
Volume 116:Number 9(2021)
Page Start:
1896
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. Issue 11 (8th September 2021)

Authors:
Gane, Edward; de Ledinghen, Victor; Dylla, Douglas E.; Rizzardini, Giuliano; Shiffman, Mitchell L.; Barclay, Stephen T.; Calleja, Jose Luis; Xue, Zhenyi; Burroughs, Margaret; Gutierrez, Julio A.
Journal:
Journal of viral hepatitis
Issue:
Volume 28:Issue 11(2021)
Page Start:
1635
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Sustained Virologic Response Predicts Fibrosis Regression Measured by FibroTest in HCV‐infected Patients: 828. (October 2016)

Authors:
Forns, Xavier; Welzel, Tania M.; Cohen, Eric; Jacobson, Ira M.; Davis, Mitchell; Reindollar, Robert; Hu, Bonnie; Dylla, Douglas E.; Enejosa, Jeffrey V.; Trinh, Roger; Sulkowski, Mark S.
Journal:
American journal of gastroenterology
Issue:
Volume 111(2016)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗